Given that the toxicity profile of anti-PD-1/anti-LAG-3 dual inhibition appears more favorable than that of anti-CTLA-4/anti-PD-1, there is a high expectation for this new ICI combination to be soon compared with the standard-of-care anti-CTLA-4/anti-PD-1, in a randomized fashion in advanced melanoma. Here, CTLA4 is linked to melanoma.